ALLMedicine™ Lipid Disorders Center

Mar 27th, 2023 - Lipid disorders are associated with the risk of cardiovascular diseases (CVDs). Remnant cholesterol (RC), a non-traditional previously neglected risk factor for CVD, has received much attention in recent years. The aim of this study is to evaluate...

Mar 23rd, 2023 - Background The early stages of atherosclerosis begin in childhood, according to multiple studies.[1] If premature development of cardiovascular disease can be anticipated during childhood, the disease might be prevented.[2] The purpose of this art...

Mar 23rd, 2023 - Background The early stages of atherosclerosis begin in childhood, according to multiple studies. [1] If premature development of cardiovascular disease can be anticipated during childhood, the disease might be prevented. [2] The purpose of this a...

Mar 23rd, 2023 - Background The early stages of atherosclerosis begin in childhood, according to multiple studies. [1] If premature development of cardiovascular disease can be anticipated during childhood, the disease might be prevented. [2] The purpose of this a...

Mar 18th, 2023 - Statins are the lipid-lowering therapy of choice for the prevention of atherosclerotic cardiovascular disease (ASCVD) but their effectiveness in lowering Low-Density Lipoprotein-Cholesterol (LDL-C) can substantially differ between individuals. In ...

Aug 13th, 2022 - Atherosclerosis begins in youth and is directly linked with the presence and severity of cardiovascular risk factors, including dyslipidemia. Thus, the timely identification and management of dyslipidemia in childhood might slow atherosclerotic pr...

Jan 12th, 2017 - Screening for Lipid Disorders in Children and Adolescents: Recommendation Statement.|2017||therapeutic use,diagnosis,therapy,diagnosis,drug therapy,

Nov 14th, 2016 - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid...

Aug 18th, 2016 - Elevations in levels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovas...

Feb 24th, 2023 - EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) is a pilot study seeking to determine the feasibility of initiating medical therapy for hyperlipidemia (HLD) in the Emergency Department (ED) and will collect data ess...

Nov 30th, 2022 - Recently, there are more and more studies show the natural herbal products can improve obesity and related metabolic disorders through changing the body composition and even body weight, but most of the studies are still at the phase of animal stu...

Nov 22nd, 2022 - The primary purpose of this discovery protocol is to identify new lipid genes from subjects with rare genetic lipids disorders. We will take advantage of the new technology of whole exome sequencing to find the cause of dyslipidemia that we haven ...

Nov 2nd, 2022 - Early detection and appropriate treatment of kidney disease is important as this may prevent future cardiovascular complications and end-organ damage more effectively than intervention in more advanced stages of disease. There is a well-establishe...

Mar 9th, 2022 - This study is proposed to all obese patients evaluated for potential bariatric surgery during a multidisciplinary evaluation for about 1 year following current french national recommendations. Demographics are collected from medical records (age, ...

Feb 9th, 2023 - HMG-CoA reductase inhibitors (statins) have been shown to effectively reduce low-density lipoprotein cholesterol (LDL-C) as well as morbidity and mortality in patients who have either atherosclerotic cardiovascular disease (ASCVD) or risk factors.

Jan 24th, 2023 - In the Atherosclerosis Risk in Communities cohort, people with carotid atherosclerosis in mid-life were more likely to have worse hearing decades later. (JAMA Otolaryngology-Head & Neck Surgery) Higher HDL cholesterol corresponded with a higher ri...

Nov 18th, 2022 - The anti-CD3 antibody teplizumab (Tzield) has become the first drug indicated to delay the progression of type 1 diabetes, the FDA announced on Thursday. Targeting the underlying autoimmune process of type 1 diabetes instead of just providing meta...

Nov 17th, 2022 - The US Food and Drug Administration (FDA) has approved the anti-CD3 monoclonal antibody teplizumab-mzwv (Tzield, Provention Bio) to delay the onset of clinical type 1 diabetes in people aged 8 years and older who are at high risk for developing th...

Nov 2nd, 2022 - The elderly transgender population is rapidly expanding and remains significantly overlooked. Although emerging evidence provides some guidance for medical and surgical treatment for transgender youth, there is still a paucity of research directed...